Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer (Q29006772)

National Institute for Occupational Safety and Health

22 March 2017

sponsor

0 references

2 references

19 July 2017

29 March 2020

2 references

19 July 2017

29 March 2020

1 reference

29 March 2020

1 reference

Islam R. Younis

1

1 reference

22 March 2017

Daniel J. George

2

1 reference

22 March 2017

Terence J. McManus

3

1 reference

22 March 2017

Herbert Hurwitz

4

1 reference

22 March 2017

Patricia Creel

5

1 reference

22 March 2017

Andrew J. Armstrong

6

1 reference

22 March 2017

Jing Jie Yu

7

1 reference

22 March 2017

Kristina Bacon

8

1 reference

22 March 2017

Gerald Hobbs

9

1 reference

22 March 2017

Cody J. Peer

10

1 reference

22 March 2017

William P. Petros

11

1 reference

22 March 2017

language of work or name

1 reference

12 March 2014

1 reference

Cancer Chemotherapy and Pharmacology

22 March 2017

published in

2 references

22 March 2017

8 December 2019

73

1 reference

22 March 2017

page(s)

991-997

1 reference

22 March 2017

issue

5

1 reference

22 March 2017

performing organization

West Virginia University

object named as

West Virginia University

1 reference

NIOSHTIC-2

on focus list of Wikimedia project

2 February 2024

Wikimedia–NIOSH collaboration

0 references

1 reference

25 September 2023

https://scigraph.springernature.com/pub.10.1007/s00280-014-2432-x

0 references

cites work

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics

23 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

23 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Targeting the endothelin axis in prostate carcinoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Association of warfarin dose with genes involved in its action and metabolism

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Cytochrome P450 and anticancer drugs

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Relationship of systemic exposure to unbound docetaxel and neutropenia.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Atrasentan: targeting the endothelin axis in prostate cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Determination of atrasentan by high performance liquid chromatography with fluorescence detection in human plasma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

3 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2432-X

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2432-X

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2432-X

Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2432-X

Dual effects of rifampin on the pharmacokinetics of atrasentan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2432-X

Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2432-X

Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2432-X

Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2432-X

Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010098

Azoles, a48 llylamines and drug metabolism

26 November 2018

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients

1 reference

12 December 2020

Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein

1 reference

12 December 2020

Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry

1 reference

12 December 2020

Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect

1 reference

12 December 2020

Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist

1 reference

12 December 2020

10.1007/S00280-014-2432-X

Identifiers

DOI

1 reference